## **Invictus Therapeutics Ltd**



ABN: 35 111 082 485

Address: Suite 4, 24 Birdwood Lane, Lane Cove,

NSW 2066 Australia

www.vgiht.com.au | Tel: +61 2 8541 4615

## VGI Health Technology Limited – Change of Company Name to Invictus Therapeutics Ltd

**Sydney, New South Wales, 1 December 2025** –VGI Health Technology Limited (VTL or the Company) is pleased to advise that in accordance with a resolution passed by its shareholders at the Company's 2025 Annual General Meeting on 28 November 2025, the change of Company name to Invictus Therapeutics Ltd has been processed by the Australian Securities and Investments Commission.

Shareholders also approved a resolution to de-list from the National Stock Exchange of Australia (the Exchange). The Company and the Exchange are finalizing the timetable for de-listing and the Company will release an announcement once that has been agreed. As the Company will be delisting from the Exchange imminently and seeking a listing on a US-based stock exchange, it has not sought a change of its NSX code.

This announcement was authorised for release by the Board of Directors.

For more information please contact:

Glenn Tong, CEO and Managing Director

Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary

Tel: +61 (0) 402 328 200

## **About Invictus Therapeutics Limited**

Invictus Therapeutics Ltd (formerly VGI Health Technology Limited (NSX:VTL)) is an Australian public listed biotechnology company developing and commercialising prescription medicines and novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD), Metabolic dysfunction-Associated Steatohepatitis (MASH), pancreatic adenocarcinoma (Pancreatic Cancer), hyperlipidaemia, hypertension and diabetes. Invictus owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a clinical development program for prescription medicines and a product development program for evidence-based nutraceuticals.